![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Kelly Broster
Kelly, a former cancer research scientist, is now focused on biopharmaceutical and pharmaceutical applications. Kelly has enjoyed spending most of her career, thus far, utilizing the power of mass spectrometry to help improve our understanding of human disease. She has a strong background in biomedical sciences, including a Masters in Biomedical Science, a PhD in Cancer Proteomics and a post-doctoral position in Systems Oncology. Kelly maintains a keen interest in biotherapeutic research and drug development and is motivated by the ability to facilitate customer success through innovative technology and powerful workflow solutions.
Company:Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com
